DGIdb - SULINDAC Drug Record

SULINDAC chembl:CHEMBL15770 ApprovedAntineoplastic

Alternate Names:

CLINORIL
MK-231
SULINDAC
CIS-5-FLUORO-2-METHYL-1-((P-METHYLSULFINYL)BENZYLIDENE)INDENE-3-ACETIC ACID
CIS-5-FLUORO-2-METHYL-1-((4-(METHYLSULFINYL)PHENYL)METHYLENE)-1H-INDENE-3-ACETIC ACID
SULINDACUM
(Z)-5-FLUORO-2-METHYL-1-((P-(METHYLSULFINYL)PHENYL)METHYLENE)-1H-INDENE-3-ACETIC ACID
SULINDACO
CLINORIL®
chembl:CHEMBL15770
pubchem.compound:1548887
rxcui:10237
chemidplus:38194-50-2
drugbank:00605

Drug Info:

Drug Class	anti-inflammatory agents, non-steroidal
Year of Approval	1978
FDA Approval	1978
Drug Class	small molecule
Drug Indications	NSAID

(6 More Sources)

Publications:

Giuliano et al., 1999, Ex vivo assay to determine the cyclooxygenase selectivity of non-steroidal anti-inflammatory drugs., Br. J. Pharmacol.
Yip-Schneider et al., 2000, Cyclooxygenase-2 expression in human pancreatic adenocarcinomas., Carcinogenesis
Fosslien, 2000, Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia., Crit Rev Clin Lab Sci
Taylor et al., 2000, Sulindac sulfone inhibits K-ras-dependent cyclooxygenase-2 expression in human colon cancer cells., Cancer Res.
Molina et al., 1999, Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs., Cancer Res.
Itano et al., 2009, Sulindac effects on inflammation and tumorigenesis in the intestine of mice with Apc and Mlh1 mutations., Carcinogenesis
Koornstra et al., 2005, Sulindac inhibits beta-catenin expression in normal-appearing colon of hereditary nonpolyposis colorectal cancer and familial adenomatous polyposis patients., Cancer Epidemiol. Biomarkers Prev.
Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
Lim et al., 1999, Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines., Biochem. Pharmacol.
Cheng et al., 2003, Cardiovascular and renal effects of cyclooxygenase inhibition in transgenic rats harboring mouse renin-2 gene (TGR[mREN2]27)., Eur. J. Pharmacol.
Soriano et al., 1999, Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines., Cancer Res.
Cheng et al., 2002, Vascular effects of COX inhibition and AT1 receptor blockade in transgenic rats harboring mouse renin-2 gene., J. Physiol. Pharmacol.
Wang ZG et al., 2013, Synthesis and SAR study of modulators inhibiting tRXRα-dependent AKT activation., Eur J Med Chem
Ferner et al., 1991, The effects of enalapril and sulindac on the dermal response to substance P and neurokinin A., Br J Clin Pharmacol
van der Sloot et al., 1995, Sulindac in established experimental diabetes: a follow-up study., Can J Neurol Sci
Sharma et al., Topical sulindac therapy in diabetic senile cataracts: cataract-IV., Indian J Ophthalmol
Jacobson et al., 1983, Diabetic complications in lens and nerve and their prevention by sulindac or sorbinil: two novel aldose reductase inhibitors., Invest. Ophthalmol. Vis. Sci.
Chaudhry et al., 1983, Inhibition of human lens aldose reductase by flavonoids, sulindac and indomethacin., Biochem. Pharmacol.
Crabbe et al., 1985, The inhibition of bovine lens aldose reductase by Clinoril, its absorption into the human red cell and its effect on human red cell aldose reductase activity., Ophthalmic Res.
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Yip-Schneider et al., Inhibition of the phosphatidylinositol 3'-kinase signaling pathway increases the responsiveness of pancreatic carcinoma cells to sulindac., J. Gastrointest. Surg.
Hedberg ML et al., 2019, Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for <i>PIK3CA</i>-altered head and neck cancer., J Exp Med
Jin et al., 2006, Synergistic induction of apoptosis by sulindac and arsenic trioxide in human lung cancer A549 cells via reactive oxygen species-dependent down-regulation of survivin., Biochem. Pharmacol.
Pyrko et al., 2006, Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo., Mol. Cancer
Wilson et al., 2002, Novel detection and differential utilization of a c-myc transcriptional block in colon cancer chemoprevention., Cancer Res.

SULINDAC AKR1B1

Interaction Score: 2.67

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
8529171 2632448 6413448 6409111 3920599 11752352

Sources:
TTD
SULINDAC TNFRSF10A

Interaction Score: 2.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16030090

Sources:
NCI
SULINDAC PTGS1

Interaction Score: 0.45

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

Mechanism of Interaction Cyclooxygenase inhibitor

PMIDs:
10372826 10484067 12586211 10626810 12512695

Sources:
TdgClinicalTrial ChemblInteractions TEND
SULINDAC FMO3

Interaction Score: 0.43

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
SULINDAC APC

Interaction Score: 0.36

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical

Response Type sensitive

PMIDs:
19755659

Sources:
JAX-CKB
SULINDAC PTGS2

Interaction Score: 0.33

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

Mechanism of Interaction Cyclooxygenase inhibitor

PMIDs:
10372826 10657949 11078056 11118042 10485483

Sources:
TdgClinicalTrial ChemblInteractions TEND
SULINDAC TAC1

Interaction Score: 0.31

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
1707646

Sources:
NCI
SULINDAC BIRC5

Interaction Score: 0.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16950207 16707021

Sources:
NCI
SULINDAC MYC

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12414619

Sources:
NCI
SULINDAC PIK3CA

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12654560 30683736

Sources:
NCI CIViC
SULINDAC RXRA

Interaction Score: 0.09

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

PMIDs:
23434637

Sources:
DTC
SULINDAC CYP2C9

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
SULINDAC CYP2C19

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
SULINDAC CYP1A2

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
SULINDAC KDM4E

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
SULINDAC CYP2D6

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
SULINDAC CYP3A4

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
SULINDAC EHMT2

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

TEND: SULINDAC
- Version: 01-August-2011
Alternate Names:

SULINDAC Primary Drug Name

Drug Info:

Year of Approval 1978

Drug Class anti-inflammatory agents, non-steroidal

Publications:
TdgClinicalTrial: SULINDAC
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications NSAID

Drug Class small molecule

FDA Approval 1978

Publications:

NCI: SULINDAC

Version: 14-September-2017

Alternate Names:

C850 NCI drug code

Drug Info:

Publications:

Pyrko et al., 2006, Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo., Mol. Cancer

Jin et al., 2006, Synergistic induction of apoptosis by sulindac and arsenic trioxide in human lung cancer A549 cells via reactive oxygen species-dependent down-regulation of survivin., Biochem. Pharmacol.

Wilson et al., 2002, Novel detection and differential utilization of a c-myc transcriptional block in colon cancer chemoprevention., Cancer Res.

DTC: SULINDAC

Version: 02-September-2020

Alternate Names:

CHEMBL15770 ChEMBL Drug ID

Drug Info:

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

Wang ZG et al., 2013, Synthesis and SAR study of modulators inhibiting tRXRα-dependent AKT activation., Eur J Med Chem

JAX-CKB: Sulindac
- Version: 27-September-2017
Alternate Names:

Drug Info:

Publications:

Itano et al., 2009, Sulindac effects on inflammation and tumorigenesis in the intestine of mice with Apc and Mlh1 mutations., Carcinogenesis
CIViC: SULINDAC
- Version: 14-September-2020
Alternate Names:

Drug Info:

Publications:

Hedberg ML et al., 2019, Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for <i>PIK3CA</i>-altered head and neck cancer., J Exp Med
TTD: Sulindac
- Version: 2020.06.01
Alternate Names:

D0Z5IU TTD Drug ID

Drug Info:

Publications:
ChemblInteractions: CHEMBL15770
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL15770
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
PharmGKB: sulindac
- Version: 18-August-2020
Alternate Names:

Drug Info:

Publications:

Trial Name	-
Novel drug target	Established target
Mechanism of Interaction	Cyclooxygenase inhibitor

Evidence Type	Actionable
Approval Status	Preclinical
Response Type	sensitive

SULINDAC Drug Record

SULINDAC chembl:CHEMBL15770 ApprovedAntineoplastic

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: 8529171 2632448 6413448 6409111 3920599 11752352

Sources: TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16030090

Sources: NCI

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name - Novel drug target Established target Mechanism of Interaction Cyclooxygenase inhibitor

PMIDs: 10372826 10484067 12586211 10626810 12512695

Sources: TdgClinicalTrial ChemblInteractions TEND

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info: Evidence Type Actionable Approval Status Preclinical Response Type sensitive

PMIDs: 19755659

Sources: JAX-CKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name - Novel drug target Established target Mechanism of Interaction Cyclooxygenase inhibitor

PMIDs: 10372826 10657949 11078056 11118042 10485483

Sources: TdgClinicalTrial ChemblInteractions TEND

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 1707646

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16950207 16707021

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12414619

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12654560 30683736

Sources: NCI CIViC

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info:

PMIDs: 23434637

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

TEND: SULINDAC

Alternate Names: SULINDAC Primary Drug Name

Drug Info: Year of Approval 1978 Drug Class anti-inflammatory agents, non-steroidal

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
8529171 2632448 6413448 6409111 3920599 11752352

Sources:
TTD

Interaction Types & Directionality:

n/a

PMIDs:
16030090

Sources:
NCI

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

Mechanism of Interaction Cyclooxygenase inhibitor

PMIDs:
10372826 10484067 12586211 10626810 12512695

Sources:
TdgClinicalTrial ChemblInteractions TEND

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical

Response Type sensitive

PMIDs:
19755659

Sources:
JAX-CKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

Mechanism of Interaction Cyclooxygenase inhibitor

PMIDs:
10372826 10657949 11078056 11118042 10485483

Sources:
TdgClinicalTrial ChemblInteractions TEND

Interaction Types & Directionality:

n/a

PMIDs:
1707646

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
16950207 16707021

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
12414619

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
12654560 30683736

Sources:
NCI CIViC

Interaction Types & Directionality:

antagonist (inhibitory)

PMIDs:
23434637

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Alternate Names:

SULINDAC Primary Drug Name

Drug Info:

Year of Approval 1978

Drug Class anti-inflammatory agents, non-steroidal

Drug Info:

Drug Indications NSAID

Drug Class small molecule

FDA Approval 1978

Alternate Names:

C850 NCI drug code

Alternate Names:

CHEMBL15770 ChEMBL Drug ID

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

Wang ZG et al., 2013, Synthesis and SAR study of modulators inhibiting tRXRα-dependent AKT activation., Eur J Med Chem

Publications:

Itano et al., 2009, Sulindac effects on inflammation and tumorigenesis in the intestine of mice with Apc and Mlh1 mutations., Carcinogenesis

Publications:

Hedberg ML et al., 2019, Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for <i>PIK3CA</i>-altered head and neck cancer., J Exp Med

Alternate Names:

D0Z5IU TTD Drug ID